The resistome of Pseudomonas seudomonas aeruginosa in relationship to phenotypic susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 427-436

  Kos, Veronica N ^a   Déraspe, Maxime ^b   McLaughlin, Robert E ^a   Whiteaker, James D ^a   Roy, Paul H ^b   Alm, Richard A ^a   Corbeil, Jacques ^b   Gardner, Humphrey ^a  

^a ASTRAZENECA   (United Kingdom)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAMASE; CARBAPENEMASE; COLISTIN; LEVOFLOXACIN; MEROPENEM; ANTIINFECTIVE AGENT; BACTERIAL DNA; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; GENETIC ANALYSIS; GENOME SIZE; GENOMIC ISLAND; GENOTYPE; GEOGRAPHY; INTEGRON; NEXT GENERATION SEQUENCING; NONHUMAN; PHENOTYPE; PHYLOGENY; POINT MUTATION; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS; BACTERIUM IDENTIFICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; NUCLEOTIDE SEQUENCE; PSEUDOMONAS INFECTIONS;

AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BASE SEQUENCE; BETA-LACTAMASES; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOME, BACTERIAL; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEQUENCE ANALYSIS, DNA; THIENAMYCINS;

EID: 84920164355     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03954-14     Document Type: Article

References (82)

1. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582-610. http://dx.doi.org/10.1128/CMR.00040-09.
2. Navon-Venezia S, Ben-Ami R, Carmeli Y. 2005. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 18:306-313. http://dx.doi.org/10.1097/01.qco .0000171920.44809.f0.
3. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194-222. http://dx.doi.org/10.1128 /CMR.15.2.194-222.2002.
4. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 43:328-334. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.007.
5. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19:419-426. http://dx.doi.org/10.1016/j.tim.2011.04.005.
6. Master RN, Deane J, Opiela C, Sahm DF. 2013. Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens. Ann N Y Acad Sci 1277:1-7. http://dx.doi.org/10.1111/nyas .12022.
7. Souli M, Galani I, Giamarellou H. 2008. Emergence of extensively drugresistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 13:19045.
8. Cortes JA, Leal AL, Montanez AM, Buitrago G, Castillo JS, Guzman L. 2013. Frequency of microorganisms isolated in patients with bacteremia in intensive care units in Colombia and their resistance profiles. Braz J Infect Dis 17:346-352. http://dx.doi.org/10.1016/j.bjid.2012.10.022.
9. Polotto M, Casella T, de Lucca Oliveira MG, Rubio FG, Nogueira ML, de Almeida MT, Nogueira MC. 2012. Detection of P. aeruginosa harboring bla CTX-M-2, bla GES-1 and bla GES-5, bla IMP-1 and bla SPM-1 causing infections in Brazilian tertiary-care hospital. BMC Infect Dis 12: 176. http://dx.doi.org/10.1186/1471-2334-12-176.
10. Dellit TH, Owens RC, McGowan JE, Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM. 2007. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159-177. http://dx.doi.org/10.1086/510393.
11. Tuite N, Reddington K, Barry T, Zumla A, Enne V. 2014. Rapid nucleic acid diagnostics for the detection of antimicrobial resistance in Gramnegative bacteria: is it time for a paradigm shift? J Antimicrob Chemother 69:1729-1733. http://dx.doi.org/10.1093/jac/dku083.
12. Zankari E, Hasman H, Kaas RS, Seyfarth AM, Agerso Y, Lund O, Larsen MV, Aarestrup FM. 2013. Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. J Antimicrob Chemother 68:771-777. http://dx.doi .org/10.1093/jac/dks496.
13. Reuter S, Ellington MJ, Cartwright EJ, Koser CU, Torok ME, Gouliouris T, Harris SR, Brown NM, Holden MT, Quail M, Parkhill J, Smith GP, Bentley SD, Peacock SJ. 2013. Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Intern Med 173:1397-1404. http://dx.doi.org/10.1001/jamainternmed .2013.7734.
14. Diekema DJ, Pfaller MA. 2013. Rapid detection of antibiotic-resistant organism carriage for infection prevention. Clin Infect Dis 56:1614-1620. http://dx.doi.org/10.1093/cid/cit038.
15. Stoesser N, Batty EM, Eyre DW, Morgan M, Wyllie DH, Del Ojo Elias C, Johnson JR, Walker AS, Peto TE, Crook DW. 2013. Predicting antimicrobial susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic sequence data. J Antimicrob Chemother 68:2234-2244.
16. Pearson WR. 1996. Effective protein sequence comparison. Methods Enzymol 266:227-258. http://dx.doi.org/10.1016/S0076-6879(96)66017-0.
17. Pearson WR, Lipman DJ. 1988. Improved tools for biological sequence comparison. Proc Natl Acad SciUSA 85:2444-2448. http://dx.doi.org/10 .1073/pnas.85.8.2444.
18. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772-780. http://dx.doi.org/10.1093/molbev/mst010.
19. Stamatakis A. 2006. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 22:2688-2690. http://dx.doi.org/10.1093/bioinformatics/btl446.
20. Boisvert S, Laviolette F, Corbeil J. 2010. Ray: simultaneous assembly of reads from a mix of high-throughput sequencing technologies. J Comput Biol 17:1519-1533. http://dx.doi.org/10.1089/cmb.2009.0238.
21. Jolley KA, Maiden MC. 2010. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 11:595. http: //dx.doi.org/10.1186/1471-2105-11-595.
22. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. 2004. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol 42:5644-5649. http: //dx.doi.org/10.1128/JCM.42.12.5644-5649.2004.
23. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389-3402. http: //dx.doi.org/10.1093/nar/25.17.3389.
24. Witney AA, Gould KA, Pope CF, Bolt F, Stoker NG, Cubbon MD, Bradley CR, Fraise A, Breathnach AS, Butcher PD, Planche TD, Hinds J. 8 February 2014. Genome sequencing and characterization of an extensively drug-resistant sequence type 111 serotype O12 hospital outbreak strain of Pseudomonas aeruginosa. Clin Microbiol Infect http://dx.doi.org /10.1111/1469-0691.12528.
25. Bruchmann S, Dotsch A, Nouri B, Chaberny IF, Haussler S. 2013. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother 57:1361-1368. http://dx.doi.org/10.1128/AAC .01581-12.
26. th ed. Approved standard M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
27. rd informational supplement M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
28. Ballarini A, Scalet G, Kos M, Cramer N, Wiehlmann L, Jousson O. 2012. Molecular typing and epidemiological investigation of clinical populations of Pseudomonas aeruginosa using an oligonucleotide-microarray. BMC Microbiol 12:152. http://dx.doi.org/10.1186/1471-2180-12-152.
29. Rau MH, Marvig RL, Ehrlich GD, Molin S, Jelsbak L. 2012. Deletion and acquisition of genomic content during early stage adaptation of Pseudomonas aeruginosa to a human host environment. Environ Microbiol 14:2200-2211. http://dx.doi.org/10.1111/j.1462-2920.2012.02795.x.
30. Jeukens J, Boyle B, Kukavica-Ibrulj I, Ouellet MM, Aaron SD, Charette SJ, Fothergill JL, Tucker NP, Winstanley C, Levesque RC. 2014. Comparative genomics of isolates of a Pseudomonas aeruginosa epidemic strain associated with chronic lung infections of cystic fibrosis patients. PLoS One 9:e87611. http://dx.doi.org/10.1371/journal.pone.0087611.
31. Warren AE, Boulianne-Larsen CM, Chandler CB, Chiotti K, Kroll E, Miller SR, Taddei F, Sermet-Gaudelus I, Ferroni A, McInnerney K, Franklin MJ, Rosenzweig F. 2011. Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections. Infect Immun 79:4802-4818. http://dx.doi.org/10.1128/IAI.05282-11.
32. Silva FM, Carmo MS, Silbert S, Gales AC. 2011. SPM-1-producing Pseudomonas aeruginosa: analysis of the ancestor relationship using multilocus sequence typing, pulsed-field gel electrophoresis, and automated ribotyping. Microb Drug Resist 17:215-220. http://dx.doi.org/10.1089 /mdr.2010.0140.
33. Viedma E, Juan C, Villa J, Barrado L, Orellana MA, Sanz F, Otero JR, Oliver A, Chaves F. 2012. VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain. Emerg Infect Dis 18:1235-1241. http://dx.doi.org/10.3201/eid1808.111234.
34. Slekovec C, Plantin J, Cholley P, Thouverez M, Talon D, Bertrand X, Hocquet D. 2012. Tracking down antibiotic-resistant Pseudomonas aeruginosa isolates in a wastewater network. PLoS One 7:e49300. http://dx .doi.org/10.1371/journal.pone.0049300.
35. Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gramnegative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35:736-755. http://dx.doi.org/10 .1111/j.1574-6976.2011.00268.x.
36. Maatallah M, Cheriaa J, Backhrouf A, Iversen A, Grundmann H, Do T, Lanotte P, Mastouri M, Elghmati MS, Rojo F, Mejdi S, Giske CG. 2011. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One 6:e25617. http://dx.doi.org/10.1371/journal.pone .0025617.
37. Hall RM, Vockler C. 1987. The region of the IncN plasmid R46 coding for resistance to beta-lactam antibiotics, streptomycin/spectinomycin and sulphonamides is closely related to antibiotic resistance segments found in IncW plasmids and in Tn21-like transposons. Nucleic Acids Res 15:7491-7501. http://dx.doi.org/10.1093/nar/15.18.7491.
38. Ouellette M, Bissonnette L, Roy PH. 1987. Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene. Proc Natl Acad Sci U S A 84:7378-7382. http://dx.doi.org/10.1073/pnas.84.21.7378.
39. Leon G, Roy PH. 2009. Potential role of group IIC-attC introns in integron cassette formation. J Bacteriol 191:6040-6051. http://dx.doi.org/10 .1128/JB.00674-09.
40. Ochs MM, Lu CD, Hancock RE, Abdelal AT. 1999. Amino acidmediated induction of the basic amino acid-specific outer membrane porin OprD from Pseudomonas aeruginosa. J Bacteriol 181:5426-5432.
41. Yoneyama H, Nakae T. 1993. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 37:2385-2390. http://dx.doi .org/10.1128/AAC.37.11.2385.
42. Lynch MJ, Drusano GL, Mobley HL. 1987. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother 31: 1892-1896. http://dx.doi.org/10.1128/AAC.31.12.1892.
43. Hancock RE, Brinkman FS. 2002. Function of Pseudomonas porins in uptake and efflux. Annu Rev Microbiol 56:17-38. http://dx.doi.org/10 .1146/annurev.micro.56.012302.160310.
44. Santella G, Pollini S, Docquier JD, Almuzara M, Gutkind G, Rossolini GM, Radice M. 2011. Carbapenem resistance in Pseudomonas aeruginosa isolates: an example of interaction between different mechanisms. Rev Panam Salud Publica 30:545-548. (In Spanish.) http://dx.doi.org/10.1590 /S1020-49892011001200008.
45. Rodriguez-Martinez JM, Poirel L, Nordmann P. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:4783-4788. http://dx.doi .org/10.1128/AAC.00574-09.
46. Strateva T, Yordanov D. 2009. Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J Med Microbiol 58:1133-1148. http://dx.doi.org /10.1099/jmm.0.009142-0.
47. Kong KF, Jayawardena SR, Indulkar SD, Del Puerto A, Koh CL, Hoiby N, Mathee K. 2005. Pseudomonas aeruginosa AmpR is a global transcriptional factor that regulates expression ofAmpCand PoxB beta-lactamases, proteases, quorum sensing, and other virulence factors. Antimicrob Agents Chemother 49:4567-4575. http://dx.doi.org/10.1128/AAC.49.11 .4567-4575.2005.
48. Smith JD, Kumarasiri M, Zhang W, Hesek D, Lee M, Toth M, Vakulenko S, Fisher JF, Mobashery S, Chen Y. 2013. Structural analysis of the role of Pseudomonas aeruginosa penicillin-binding protein 5 in betalactam resistance. Antimicrob Agents Chemother 57:3137-3146. http://dx .doi.org/10.1128/AAC.00505-13.
49. Okamoto K, Gotoh N, Nishino T. 2002. Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J Infect Chemother 8:371-373. http://dx.doi.org/10.1007/s10156-002-0193-7.
50. Livermore DM. 2001. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 47:247-250. http://dx.doi.org/10.1093/jac /47.3.247.
51. Barnard FM, Maxwell A. 2001. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob Agents Chemother 45:1994-2000. http://dx.doi .org/10.1128/AAC.45.7.1994-2000.2001.
52. Yoshida H, Nakamura M, Bogaki M, Nakamura S. 1990. Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34:1273-1275. http://dx.doi .org/10.1128/AAC.34.6.1273.
53. Jacoby GA. 2005. Mechanisms of resistance to quinolones. Clin Infect Dis 41(Suppl 2):S120-S126. http://dx.doi.org/10.1086/428052.
54. Mouneimne H, Robert J, Jarlier V, Cambau E. 1999. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 43:62-66.
55. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12:83-88. http://dx.doi.org/10.1038/nm1347.
56. Doi Y, de Oliveira Garcia D, Adams J, Paterson DL. 2007. Coproduction of novel 16SrRNAmethylaseRmtDand metallo-beta-lactamaseSPM-1in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother 51:852-856. http://dx.doi.org/10.1128/AAC.01345-06.
57. Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2:65. http://dx.doi.org/10.3389/fmicb.2011.00065.
58. Poole K. 2005. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56:20-51. http://dx.doi.org/10.1093/jac/dki171.
59. Aghazadeh M, Hojabri Z, Mahdian R, Nahaei MR, Rahamti M, Hojabri T, Pirzadeh T, Pajand O. 2014. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-beta-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients. Infect Genet Evol 24:187-192. http://dx .doi.org/10.1016/j.meegid.2014.03.018.
60. Muller C, Plesiat P, Jeannot K. 2011. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 55:1211-1221. http://dx.doi.org/10.1128/AAC.01252-10.
61. Roy PH, Tetu SG, Larouche A, Elbourne L, Tremblay S, Ren Q, Dodson R, Harkins D, Shay R, Watkins K, Mahamoud Y, Paulsen IT. 2010. Complete genome sequence of the multiresistant taxonomic outlier Pseudomonas aeruginosa PA7. PLoS One 5:e8842. http://dx.doi.org/10.1371 /journal.pone.0008842.
62. Fernandez L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock RE. 2010. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob Agents Chemother 54:3372-3382. http://dx.doi.org/10.1128/AAC.00242-10.
63. Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Hoiby N, Moskowitz SM. 2011. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 55:5761-5769. http://dx.doi.org/10.1128/AAC.05391-11.
64. Lee JY, Na IY, Park YK, Ko KS. 2014. Genomic variations between colistin-susceptible and -resistant Pseudomonas aeruginosa clinical isolates and their effects on colistin resistance. J Antimicrob Chemother 69:1248-1256. http://dx.doi.org/10.1093/jac/dkt531.
65. Card R, Zhang J, Das P, Cook C, Woodford N, Anjum MF. 2013. Evaluation of an expanded microarray for detecting antibiotic resistance genes in a broad range of Gram-negative bacterial pathogens. Antimicrob Agents Chemother 57:458-465. http://dx.doi.org/10.1128/AAC.01223-12.
66. Li XZ, Poole K, Nikaido H. 2003. Contributions of MexAB-OprM and an EmrE homolog to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. Antimicrob Agents Chemother 47:27-33. http://dx .doi.org/10.1128/AAC.47.1.27-33.2003.
67. Sobel ML, McKay GA, Poole K. 2003. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 47:3202-3207. http://dx.doi.org/10.1128/AAC.47.10.3202-3207.2003.
68. Pulido MR, Garcia-Quintanilla M, Martin-Pena R, Cisneros JM, Mc-Connell MJ. 2013. Progress on the development of rapid methods for antimicrobial susceptibility testing. J Antimicrob Chemother 68:2710-2717. http://dx.doi.org/10.1093/jac/dkt253.
69. Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, Phan MD, Gomes Moriel D, Peters KM, Davies M, Rogers BA, Dougan G, Rodriguez-Bano J, Pascual A, Pitout JD, Upton M, Paterson DL, Walsh TR, Schembri MA, Beatson SA. 2014. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 111: 5694-5699. http://dx.doi.org/10.1073/pnas.1322678111.
70. Deleo FR, Chen L, Porcella SF, Martens CA, Kobayashi SD, Porter AR, Chavda KD, Jacobs MR, Mathema B, Olsen RJ, Bonomo RA, Musser JM, Kreiswirth BN. 2014. Molecular dissection of the evolution of car-bapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci U S A 111:4988-4993. http://dx.doi.org/10.1073/pnas .1321364111.
71. Horvath P, Barrangou R. 2010. CRISPR/Cas, the immune system of bacteria and archaea. Science 327:167-170. http://dx.doi.org/10.1126 /science.1179555.
72. Marraffini LA, Sontheimer EJ. 2010. CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 11:181-190. http://dx.doi.org/10.1038/nrg2749.
73. Bondy-Denomy J, Pawluk A, Maxwell KL, Davidson AR. 2013. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature 493:429-432. http://dx.doi.org/10.1038/nature11723.
74. Cady KC, Bondy-Denomy J, Heussler GE, Davidson AR, O'Toole GA. 2012. The CRISPR/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages. J Bacteriol 194:5728-5738. http://dx.doi.org/10.1128/JB.01184-12.
75. Pawluk A, Bondy-Denomy J, Cheung VH, Maxwell KL, Davidson AR. 2014. A new group of phage anti-CRISPR genes inhibits the type I-E CRISPR-Cas system of Pseudomonas aeruginosa. mBio 5(2):e00896 -14. http://dx.doi.org/10.1128/mBio.00896-14.
76. Palmer KL, Gilmore MS. 2010. Multidrug-resistant enterococci lack CRISPRcas. mBio 1(4):e00227-10. http://dx.doi.org/10.1128/mBio.00227-10.
77. Koser CU, Holden MT, Ellington MJ, Cartwright EJ, Brown NM, Ogilvy-Stuart AL, Hsu LY, Chewapreecha C, Croucher NJ, Harris SR, Sanders M, Enright MC, Dougan G, Bentley SD, Parkhill J, Fraser LJ, Betley JR, Schulz-Trieglaff OB, Smith GP, Peacock SJ. 2012. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med 366:2267-2275. http://dx.doi.org/10.1056/NEJMoa1109910.
78. Harris SR, Cartwright EJ, Torok ME, Holden MT, Brown NM, Ogilvy-Stuart AL, Ellington MJ, Quail MA, Bentley SD, Parkhill J, Peacock SJ. 2013. Whole-genome sequencing for analysis of an outbreak of meticillinresistant Staphylococcus aureus: a descriptive study. Lancet Infect Dis 13: 130-136. http://dx.doi.org/10.1016/S1473-3099(12)70268-2.
79. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, Klammer A, Peluso P, Lee L, Kislyuk AO, Bullard J, Kasarskis A, Wang S, Eid J, Rank D, Redman JC, Steyert SR, Frimodt-Moller J, Struve C, Petersen AM, Krogfelt KA, Nataro JP, Schadt EE, Waldor MK. 2011. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany.NEngl J Med 365:709-717. http://dx.doi.org/10.1056/NEJMoa1106920.
80. Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR, Rico A, Prior K, Szczepanowski R, Ji Y, Zhang W, McLaughlin SF, Henkhaus JK, Leopold B, Bielaszewska M, Prager R, Brzoska PM, Moore RL, Guenther S, Rothberg JM, Karch H. 2011. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS One 6:e22751. http://dx.doi.org/10.1371/journal.pone.0022751.
81. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, Segre JA. 2012. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 4:148ra116. http://dx.doi.org/10.1126/scitranslmed.3004129.
82. Ho CC, Yuen KY, Lau SK, Woo PC. 2011. Rapid identification and validation of specific molecular targets for detection of Escherichia coli O104:H4 outbreak strain by use of high-throughput sequencing data from nine genomes. J Clin Microbiol 49:3714-3716. http://dx.doi.org/10.1128 /JCM.05062-11.